Alzheimer's disease

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Friday, March 1, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

Retrieved on: 
Friday, March 1, 2024
OSI, Court, FDA, Food, Advertising, Alzheimer's disease, GCP, Risk, COVID-19, Good clinical practice, Patient, Clinical trial, LLP, Defendant, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioVie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

Retrieved on: 
Thursday, February 29, 2024
ALS Association, Senior, ALS, Research, Alzheimer's disease, TFEB, Wang, Neuron, ALP, Hope, Trehalose, Neurodegenerative disease, Protein, Patient, Spinal cord, Gene, Disease, CSO, Diagnosis, Autophagy, AAV, Amyotrophy, Brain

The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .

Key Points: 
  • The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .
  • ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
  • Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe.
  • With this funding and invaluable support from the ALS Association, we are poised to move our CTx-TFEB program forward.

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024
Research, ARIA, FLNA, Drug development, ADAS, Exercise, ADAS-Cog, Private law, Mass spectrometry, Criterion, CDR, Bawskee 3.5, Protein, Intellectual property, Patient, Plasma, Cassava Sciences, PET, MRI, City University, Hyperkinesia, Cerebrospinal fluid, Edema, Cassava, Memory, Insulin, G&A, Tablet, Brain, City, CUNY, SAP, Calendar, Completion, Safety, Clinical, Knowledge, Alzheimer's disease, Magnetic resonance imaging, Blood, FDA, Ageing, Food, Data, Lymphocyte, Medicine, DSMB, Pharmaceutical industry

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.

Reliq Health Technologies, Inc. Announces Expansion of Mental Health Services

Retrieved on: 
Tuesday, February 27, 2024
Live, BHI, Alzheimer's disease, Nursing, Mental health, CMS, Dementia, RHT, Health care, Medicare, Patient, Mental, WKN

“We are very pleased to be adding cognitive assessments to our portfolio of mental health services,” said Chris Shields, CEO at Reliq Health Technologies, Inc. “Many of our existing and potential clients have requested that Reliq offer additional products and services in the mental healthcare area, particularly for patients in Skilled Nursing and Assisted Living Facilities.

Key Points: 
  • “We are very pleased to be adding cognitive assessments to our portfolio of mental health services,” said Chris Shields, CEO at Reliq Health Technologies, Inc. “Many of our existing and potential clients have requested that Reliq offer additional products and services in the mental healthcare area, particularly for patients in Skilled Nursing and Assisted Living Facilities.
  • Providing cognitive assessments to our patient populations, will allow clinicians to identify patients with previously undiagnosed mental health needs.
  • Medicare has increased the reimbursement rate for Behavioral Health Integration (BHI) by 25% in 2024 as part of their ongoing commitment to improving mental health in at-risk patient populations.
  • The Company will initially roll out its expanded mental health services to existing Skilled Nursing and Assisted Living Facilities as well as Alzheimer and Dementia Care (Memory Care) Facilities.

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Reactive oxygen species, Alzheimer's disease, MicroRNA, Inflammation, OTC, LPS, Schizophrenia, Nitric oxide, Cell, Factorization of polynomials, Safety, Protein, Clinical trial, Gene, DSM-IV codes, ROS, Hebrew University of Jerusalem, Microglia, Anoxic waters, Spectrum, Al-Quds, Research, Cannabidiol, Pharmaceutical industry

Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.

Key Points: 
  • Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.
  • The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model.
  • “We are excited to finally receive the positive results from our preclinical study, which was our first step in validating our novel, cannabinoid based therapeutic,” said Aitan Zacharin, GCANRx CEO.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024
Shift, Therapy, Epigenomics, Central nervous system, Alzheimer's disease, KCNK10, Astrocyte, Date, Conference, Mechanism, CNS, Gene, DSM-IV codes

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
OSI, Court, FDA, Food, Advertising, Alzheimer's disease, GCP, Risk, Woman, COVID-19, Good clinical practice, Patient, Clinical trial, LLP, Defendant, Pharmaceutical industry

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Upon trial completion, the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioVie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.